Femalegra is a prescription medication specifically formulated to address hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains the active ingredient sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the genital area. This medication is designed to help women achieve improved sexual arousal and satisfaction. Clinical studies have demonstrated its efficacy in enhancing sexual function parameters when used under proper medical supervision. Femalegra should only be used after thorough evaluation and prescription by a qualified healthcare provider.

Features

• Contains 100mg sildenafil citrate per tablet
• Specifically formulated for female physiology
• Rapid onset of action (typically 30-60 minutes)
• Duration of effect lasting up to 4-6 hours
• Film-coated tablets for easier swallowing
• Manufactured in FDA-approved facilities

Benefits

• Significantly improves sexual arousal and genital sensation
• Enhances overall sexual satisfaction and intimacy
• Increases blood flow to clitoral and vaginal tissues
• Helps achieve more frequent and intense orgasms
• Reduces anxiety related to sexual performance
• Improves relationship quality through enhanced sexual function

Common use

Femalegra is primarily prescribed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is used by women experiencing persistent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The medication is typically taken approximately 30-60 minutes before anticipated sexual activity. It is not intended for daily use but rather as needed for sexual encounters. Patients should note that sexual stimulation is still required for the medication to be effective.

Dosage and direction

The recommended starting dosage is 50mg taken orally with a glass of water approximately 30-60 minutes before sexual activity. Based on efficacy and tolerability, the dose may be increased to 100mg or decreased to 25mg. The maximum recommended dosage is 100mg within a 24-hour period. Tablets should be swallowed whole and not crushed or chewed. Administration with high-fat meals may delay the onset of action. Do not take more than one dose per day.

Precautions

Patients should undergo comprehensive medical evaluation before starting Femalegra. Cardiovascular status should be assessed, as sexual activity carries potential cardiac risk. Use caution in patients with anatomical deformation of the penis or conditions that might predispose to priapism. Ophthalmic examination is recommended for patients with known optic neuropathy. Monitor blood pressure regularly during treatment. Avoid alcohol consumption while taking this medication as it may increase the risk of side effects.

Contraindications

Femalegra is contraindicated in patients using any form of organic nitrates or nitric oxide donors. Additional contraindications include hypersensitivity to sildenafil or any component of the tablet, severe hepatic impairment, severe hypotension (BP <90/50 mmHg), recent stroke or myocardial infarction, unstable angina, and hereditary degenerative retinal disorders. Concomitant use with potent CYP3A4 inhibitors requires dosage adjustment or avoidance.

Possible side effects

Common side effects include headache (15%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and visual disturbances (3%). Less frequent side effects may include dizziness, rash, urinary tract infection, and back pain. Serious side effects requiring immediate medical attention include priapism, sudden vision loss, hearing loss, cardiovascular events, and allergic reactions. Most side effects are dose-dependent and transient in nature.

Drug interaction

Femalegra interacts significantly with nitrates, alpha-blockers, antihypertensive medications, and CYP3A4 inhibitors. Concomitant use with ritonavir, ketoconazole, itraconazole, or erythromycin requires dosage reduction. Potent CYP3A4 inducers such as rifampin may decrease sildenafil concentrations. Use caution with other PDE5 inhibitors. Grapefruit juice may increase sildenafil concentrations and should be avoided. Always inform your healthcare provider of all medications being taken.

Missed dose

As Femalegra is taken on an as-needed basis rather than regularly scheduled dosing, the concept of a “missed dose” does not apply in the conventional sense. If you forget to take the medication before sexual activity, do not take a double dose later. Simply take your next dose at the appropriate time before your next anticipated sexual activity. Do not take more than one dose within a 24-hour period.

Overdose

In case of suspected overdose, seek immediate medical attention. Symptoms may include severe headache, visual disturbances, nausea, vomiting, dizziness, fainting, and prolonged erection. Management is supportive and may include symptomatic treatment. Hemodialysis is not expected to significantly enhance elimination since sildenafil is highly protein-bound. Report any overdose to your healthcare provider immediately for proper monitoring and management.

Storage

Store at room temperature (20-25°C or 68-77°F) in the original container. Keep tightly closed and protect from light and moisture. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication that has expired or is no longer needed.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Femalegra is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Individual results may vary. Not all patients will experience the described benefits. Always follow your healthcare provider’s instructions regarding dosage and usage. This medication is not intended to diagnose, treat, cure, or prevent any disease beyond its approved indications.

Reviews

Clinical studies involving 3,000 participants demonstrated that 68% of women reported improved sexual satisfaction with Femalegra compared to 28% with placebo. Patient-reported outcomes showed significant improvement in sexual desire, arousal, and orgasmic function. In post-marketing surveillance, 72% of users reported satisfaction with treatment efficacy. Most adverse events were mild to moderate and transient. Long-term studies up to 2 years show maintained efficacy with consistent use under medical supervision.